Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)

NCT00423800 | Terminated Phase 3 Results

• 1 other identifier: P05016
• Study Type: interventional
• Target: 56
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a Phase IIIB randomized, controlled, multi-centre, open-label study of 24 versus 48 weeks therapy with Pegetron® (peginterferon alfa-2b + ribavirin) at standard doses in naïve Hepatitis C Virus (HCV) genotype 1 high viral load (HVL) participants who are Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) negative at Week 4. HVL will be defined as HCV-RNA of \>600,000 IU/mL prior to the initiation of therapy. Participants with genotype 1 baseline HVL prescribed Pegetron® (peginterferon and ribavirin) in the usual manner in accordance with the marketing authorization and who are viral negative at Week 4 will be randomized at Week 8 to receive a total of 24 or 48 weeks of therapy. Participants will be required to have their baseline and Week-12 viral load analyzed by the same local laboratory using the standard of care test used by the site. Qualitative testing at Week 4, 8, 16-20, 24, and 48 may be conducted either by local laboratory or a central laboratory identified by the sponsor using an assay specified by the sponsor. No additional interventions outside of the clinic's standard of care and the conditions of the Canadian product monograph for Pegetron® will be applied to participants.

Conditions

Hepatitis C, Chronic

Outcome Measures

Primary Outcomes (1)

• Number of Participants With a Sustained Virologic Response

  Participants were tested for the presence of Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) in blood by Qualitative Polymerase Chain Reaction (qPCR). If the HCV-RNA is not detectable, the participant is negative for HCV-RNA. Sustained virologic responders were participants negative for HCV-RNA at 24 weeks following the completion of therapy. A Participant that withdrew prior to 24 weeks following the completion of therapy was considered a non-responder.

  24 weeks following completion of 24 or 48 weeks of therapy

Secondary Outcomes (1)

• Number of Participants With a Virological Relapse

  24 weeks following completion of 24 or 48 weeks of therapy

Study Arms (2)

Pegetron® - 24 Weeks

EXPERIMENTAL

Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 16 weeks of treatment

Drug: Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)

Pegetron®- 48 Weeks

ACTIVE COMPARATOR

Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 40 weeks of treatment.

Drug: Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)

Interventions

Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV) DRUG

1. Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks 2. 200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks

Also known as: PEGETRON® combination therapy, (a) SCH 54031, PEGETRON® (peginterferon alfa-2b) Powder for Solution, (b) SCH 18908, PEGETRON® (ribavirin) Capsules

Pegetron® - 24 Weeks; Pegetron®- 48 Weeks

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Must demonstrate willingness to participate in the study.
• Diagnosed with chronic HCV.
• Between 18 and 65 years of age of either gender and of any race.
• a. HCV positive, \>600,000 IU/mL at baseline AND b. Genotype 1.
• Suitable for treatment with Pegetron® per the Canadian product monograph.
• Investigator has already decided to treat with PEGETRON REDIPEN®
• mcg/kg/week of peginterferon alpha-2b plus 800-1200 mg /day of ribavirin.
• HCV-RNA negative at treatment week 4.
• Meet certain minimum laboratory values at the week 4 screening visit.
• Women of childbearing potential and male partners must agree to use a medically accepted method of contraception prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication. Acceptable methods of contraception include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed IUD, oral or injectable hormonal contraceptive, and surgical sterilization (e.g. hysterectomy or tubal ligation).

You may not qualify if:

• Had previous interferon-based therapy for Chronic Hepatitis C.
• Active Hepatitis B virus (HBV) infection.
• Human Immunodeficiency Virus (HIV) antibody positive.
• Cirrhotic (Stage 4 on Metavir system).
• Uncontrolled history or current severe depression or psychoses.
• Uncontrolled epilepsy.
• Use of illicit drugs.
• History of non-compliance to medical regimens.
• Liver disease other than from chronic hepatitis C.
• Participating in any other clinical study.
• Used any investigational drugs within 30 days of screening.
• Participants weighing \< 40 kg or \> 125 kg.
• Pregnant women or women who plan to become pregnant or sexual partners of women who want to become pregnant.

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

MeSH Terms

Conditions

Hepatitis C, Chronic

Interventions

Ribavirin; peginterferon alfa-2b; Powders; Solutions; Capsules

Condition Hierarchy (Ancestors)

Hepatitis C; Blood-Borne Infections; Communicable Diseases; Infections; Hepatitis, Viral, Human; Virus Diseases; Flaviviridae Infections; RNA Virus Infections; Hepatitis, Chronic; Hepatitis; Liver Diseases; Digestive System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Ribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Dosage Forms; Pharmaceutical Preparations

Limitations and Caveats

Due to the small sample size (n=5), no conclusions should be drawn.

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 17, 2007
• First Posted: January 18, 2007
• Study Start: December 1, 2006
• Primary Completion: October 1, 2009
• Study Completion: October 1, 2009
• Last Updated: April 7, 2017
• Results First Posted: February 23, 2011

Record last verified: 2017-03

Data Sharing

• IPD Sharing: Will share